CPL500036

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05297201 (ClinicalTrials.gov)	November 2, 2021	17/2/2022	Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia	Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potenti ...	Parkinson Disease;Dyskinesia, Medication-Induced	Drug: CPL500036 - low dose;Drug: CPL500036 - high dose;Drug: Placebo	Celon Pharma SA	National Center for Research and Development, Poland	Recruiting	50 Years	80 Years	All	108	Phase 2	Poland
2	EUCTR2020-006004-16-PL (EUCTR)	16/07/2021	23/04/2021	Phase II clinical trial to assess anti-dyskinetic efficacy of CPL500036, in patients with levodopa-i ...	Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potenti ...	Levodopa-induced dyskinesia in Parkinson's Disease;Therapeutic area: Diseases [C] - Nervous System D ...	Product Code: PG203 INN or Proposed INN: CPL500036 Other descriptive name: CPL500036	Celon Pharma S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	108	Phase 2	Poland

First Previous1Next Last